We are live on ! Find out more
KCM

Kingdon Capital Management Portfolio holdings

AUM $911M
1-Year Est. Return 51.11%
This Fund
S&P 500
This Quarter Est. Return
+26.25%
1 Year Est. Return
+51.11%
3 Year Est. Return
+185.44%
5 Year Est. Return
+284.29%
10 Year Est. Return
+2,022.7%
AUM
$925M
AUM Growth
+$33.9M
Cap. Flow
-$117M
Cap. Flow %
-12.67%
Top 10 Hldgs %
56.49%
Holding
80
New
21
Increased
13
Reduced
13
Closed
24

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$28.4M
2
XLRN
Acceleron Pharma
XLRN
+$26.9M
3
PRPL icon
Purple Innovation
PRPL
+$19.6M
4
SPLK
Splunk Inc
SPLK
+$15.8M
5
NOMD icon
Nomad Foods
NOMD
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 25.01%
2 Consumer Discretionary 12.8%
3 Communication Services 9.57%
4 Industrials 8.63%
5 Technology 8.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WSC icon
76
WillScot Mobile Mini Holdings
WSC
$4.41B
-420,121
Closed -$7.01M
SPLK
77
DELISTED
Splunk Inc
SPLK
-83,861
Closed -$15.8M
AERI
78
DELISTED
Aerie Pharmaceuticals
AERI
-843,940
Closed -$9.93M
KSU
79
DELISTED
Kansas City Southern
KSU
-50,625
Closed -$9.15M
IMMU
80
DELISTED
Immunomedics Inc
IMMU
-71,400
Closed -$6.07M

Similar funds

Kingdon Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Kingdon Capital Management held 80 positions worth $925M, up 3.8% from $891M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Kingdon Capital Management withdrew a net $117M in Q4 2020, closing 24 positions and reducing 13 holdings. Its most notable exit was Merck, an estimated $28.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, Kingdon Capital Management opened a new position in Baidu worth $22.9M.

  • Kingdon Capital Management's largest Q4 2020 buy was Baidu: 105,815 shares worth $22.9M.
  • Kingdon Capital Management added most to Lithia Motors in Q4 2020, an estimated $7.62M increase.
  • Kingdon Capital Management's biggest Q4 2020 reduction was Acceleron Pharma, cutting an estimated $26.9M.
  • Kingdon Capital Management fully exited Merck in Q4 2020, selling an estimated $28.4M.
  • Kingdon Capital Management's ten largest holdings make up 56% of its $925M portfolio in Q4 2020.
  • Kingdon Capital Management opened 21 new positions and closed 24 in Q4 2020.
  • Kingdon Capital Management's portfolio value rose 3.8% quarter-over-quarter to $925M.

Based on Kingdon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.